• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
Publication date: 24–30 August 2019Source: The Lancet, Volume 394, Issue 10199Author(s): Gholamreza Roshandel, Masoud Khoshnia, Hossein Poustchi, Karla Hemming, Farin Kamangar, Abdolsamad Gharavi, Mohammad Reza Ostovaneh, Alireza Nateghi, Masoud Majed, Behrooz Navabakhsh, Shahin Merat, Akram Pourshams, Mahdi Nalini, Fatemeh Malekzadeh, Masoumeh Sadeghi, Noushin Mohammadifard, Nizal Sarrafzadegan, Mohammad Naemi-Tabiei, Abdolreza Fazel, Paul BrennanSummaryBackgroundA fixed-dose combination therapy (polypill strategy) has been proposed as an approach to reduce the burden of cardiovascular disease, especially in low-income ...
Source: The Lancet - August 23, 2019 Category: General Medicine Source Type: research

This Daily Pill Cut Heart Attacks by Half. Why Isn ’t Everyone Getting It?
“Polypills” of generic drugs may dramatically reduce heart attacks and strokes in poor countries, a new study suggests. Some experts still aren’t enthusiastic.
Source: NYT Health - August 22, 2019 Category: Consumer Health News Authors: Donald G. McNeil Jr. Tags: Heart Drugs (Pharmaceuticals) Blood Pressure Aspirin Stroke Statins (Cholesterol-Lowering Drugs) Lancet, The (Journal) Frieden, Thomas R World Health Organization Tehran University University of Birmingham Iran Polypill your-feed Source Type: news

Apelin-13 Suppresses Neuroinflammation Against Cognitive Deficit in a Streptozotocin-Induced Rat Model of Alzheimer ’s Disease Through Activation of BDNF-TrkB Signaling Pathway
Conclusion The data in this manuscript demonstrates that apelin-13 upregulates BDNF against STZ-induced congnitive impairment by suppressing glial cell activity and inflammatory factors release. This suggests apelin signaling may be a new target in the treatment of AD. Ethics Statement All experimental protocols were carried out according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals approved by the Central South University at XiangYa Animal Care and Use Committee. Author Contributions XqQ and LH conceived the study and contributed to its experimental design. HqL carried out the...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Drug Use for Secondary Prevention of Cardiovascular Diseases in Golestan, Iran: Results From the Golestan Cohort Study.
CONCLUSION: Drug use after IHD or stroke is low in Northeast of Iran. Comprehensive efforts to promote secondary prevention are urgently needed. PMID: 29688733 [PubMed - in process]
Source: Archives of Iranian Medicine - March 1, 2018 Category: Middle East Health Authors: Nalini M, Sepanlou SG, Pourshams A, Poustchi H, Sharafkhah M, Bahrami H, Kamangar F, Malekzadeh R Tags: Arch Iran Med Source Type: research